81
Participants
Start Date
October 31, 2011
Primary Completion Date
November 30, 2012
Study Completion Date
May 31, 2014
SAR302503
"Pharmaceutical form:capsule~Route of administration: oral"
Investigational Site Number 036003, Randwick
Investigational Site Number 036004, Kogarah
Investigational Site Number 036002, Kingswood
Investigational Site Number 036001, Clayton
Investigational Site Number 380004, Orbassano
Investigational Site Number 250003, Marseille
Investigational Site Number 724003, Madrid
Investigational Site Number 250004, Brest
Investigational Site Number 380003, Bologna
Investigational Site Number 380001, Florence
Investigational Site Number 840007, Rochester
Investigational Site Number 276004, Frankfurt am Main
Investigational Site Number 840003, St Louis
Investigational Site Number 276003, Mannheim
Investigational Site Number 250001, Paris
Investigational Site Number 840001, Houston
Investigational Site Number 840005, Los Angeles
Investigational Site Number 840004, La Jolla
Investigational Site Number 840011, Palo Alto
Investigational Site Number 840008, Scottsdale
Investigational Site Number 840010, Ann Arbor
Investigational Site Number 124002, Montreal
Investigational Site Number 124003, Toronto
Investigational Site Number 124001, Vancouver
Investigational Site Number 410001, Seongnam
Investigational Site Number 410003, Seoul
Investigational Site Number 410004, Seoul
Investigational Site Number 410002, Seoul
Investigational Site Number 724004, Badalona
Investigational Site Number 724001, Barcelona
Investigational Site Number 724002, Valencia
Investigational Site Number 826001, Belfast
Investigational Site Number 826006, Birmingham
Investigational Site Number 826003, London
Investigational Site Number 826004, London
Lead Sponsor
Bristol-Myers Squibb
INDUSTRY